Recursion

Recursion company information, Employees & Contact Information

Explore related pages

Related company profiles:

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine. Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montréal, New York, London, Oxford area, and the San Francisco Bay area. Learn more at www.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Company Details

Employees
846
Founded
-
Address
41 S Rio Grande St, Salt Lake City,utah 84101,united States
Phone
385-269-0203
Email
in****@****rma.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Salt Lake City, Utah
Looking for a particular Recursion employee's phone or email?

Recursion Questions

News

Recursion Pharma CEO Gibson sells $570,000 in shares - Investing.com India

Recursion Pharma CEO Gibson sells $570,000 in shares Investing.com India

Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) - Seeking Alpha

Recursion Pharma to reduce workforce by 20% (RXRX:NASDAQ) Seeking Alpha

Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? - Yahoo Finance

Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? Yahoo Finance

Why Is Recursion Pharma Stock Surging On Monday? - Recursion Pharmaceuticals (NASDAQ:RXRX) - Benzinga

Why Is Recursion Pharma Stock Surging On Monday? - Recursion Pharmaceuticals (NASDAQ:RXRX) Benzinga

SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge - Stocktwits

SoftBank Joins Nvidia In Backing Recursion Pharma, Retail Traders Rally Behind Stock Surge Stocktwits

Recursion pharma director Khan sells $202k in shares - Investing.com

Recursion pharma director Khan sells $202k in shares Investing.com

Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets - ACS Publications

Discovery of a Novel DCAF1 Ligand Using a Drug–Target Interaction Prediction Model: Generalizing Machine Learning to New Drug Targets ACS Publications

BPS Publications - British Pharmacological Society | Journals

BPS Publications British Pharmacological Society | Journals

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases - Bayer

Bayer collaborates with Recursion to strengthen digital drug discovery and advance new therapies for fibrotic diseases Bayer

Tapping Into AI ML Partnerships To Advance Drug Discovery With Recursion Pharma - Clinical Leader

Tapping Into AI ML Partnerships To Advance Drug Discovery With Recursion Pharma Clinical Leader

Recursion Pharma Sharpens Oncology Focus with Potential $1.5B Bayer Collaboration - Inside Precision Medicine

Recursion Pharma Sharpens Oncology Focus with Potential $1.5B Bayer Collaboration Inside Precision Medicine

Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN

Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data MSN

Recursion Pharma nets $239M, plus an AI research contract with Bayer - Fierce Biotech

Recursion Pharma nets $239M, plus an AI research contract with Bayer Fierce Biotech

Recursion Pharma CEO Gibson sells shares worth $3.26 million - Investing.com

Recursion Pharma CEO Gibson sells shares worth $3.26 million Investing.com

Recursion Secures $239 Million in Equity Financing to - GlobeNewswire

Recursion Secures $239 Million in Equity Financing to GlobeNewswire

H. Perry Fell, Experienced BioTech Executive, Joins Board of Recursion Pharmaceuticals - PR.com

H. Perry Fell, Experienced BioTech Executive, Joins Board of Recursion Pharmaceuticals PR.com

The subtle art of really big data: Recursion Pharma maps the body - ZDNET

The subtle art of really big data: Recursion Pharma maps the body ZDNET

Recursion Pharma acquires digital vivarium outfit Vium - Fierce Biotech

Recursion Pharma acquires digital vivarium outfit Vium Fierce Biotech

Top Recursion Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant